Pregnancy Outcomes in Chinese Patients with Systemic Lupus Erythematosus (SLE): A Retrospective Study of 109 Pregnancies

Ming Ku, Shuiming Guo, Weifeng Shang, Qing Li, Rui Zeng, Min Han, Shuwang Ge*, Gang Xu*

Division of Nephrology, Department of Internal Medicine, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

* geshuwang@tjh.tjmu.edu.cn (SWG); xugang@tjh.tjmu.edu.cn (GX)

Abstract

Systemic lupus erythematosus (SLE) is a multisystem autoimmune disease that primarily affects women during their reproductive years. The interaction between SLE and pregnancy remains debated. The objective of this study was to analyze the fetal and maternal outcomes of Chinese women with SLE. A total of 109 pregnancies in 83 SLE patients from June 2004 to June 2014 at a tertiary university hospital were reviewed retrospectively. Patients’ characteristics, clinical and laboratory data during pregnancy were obtained from electronic medical records. After exclusion of elective abortions, the live birth rate was 61.5%. Significantly, APS (antiphospholipid syndrome), disease activity, hypertension, hypocomplementemia, thrombocytopenia, and anemia during pregnancy were more commonly observed in fetal loss pregnancies than in live birth pregnancies. Compared to the 64 women with a history of SLE, 19 women with new-onset lupus during pregnancy had worse pregnancy outcome. Furthermore, the 64 patients with a history of SLE were divided into lupus nephritis group and SLE group (non-renal involvement). We found that the lupus nephritis group had worse maternal outcome than the SLE group. We conclude that new-onset lupus during pregnancy predicts both adverse maternal and fetal outcomes, while a history of lupus nephritis predicts adverse maternal outcomes. It is essential to provide SLE women with progestational counseling and regular multispecialty care during pregnancy.

Introduction

Systemic lupus erythematosus (SLE) is a complex, multisystem disease that mainly attacks fertile women. Women with lupus disease are not less fertile than unaffected women, but SLE may increase pregnancy complications, including spontaneous abortion, premature delivery, intrauterine growth restriction (IUGR), and preeclampsia[1]. Although recent studies have shown favorable outcomes[2–6] such as the improved survival rate and the timing of conception after SLE remissive from longer than 6 months to 4 months[7], SLE remains a disease...
associated with significant fetal and maternal complications[8–10]. The interaction of SLE and pregnancy has been studied but still under debate.

Several studies suggested that renal function and the presence of proteinuria at the time of conception may contribute to adverse maternal and fetal outcomes[7,11–13]. However, some reports showed that the women with a history of lupus nephritis can also have successful pregnancy outcomes[14–17]. Furthermore, new-onset of SLE can even occur during pregnancy [13,18,19]. A study suggested that new-onset SLE during pregnancy generally occurred during the second trimester, with a higher rate of renal and blood involvement[20]. However, there are limited researches associated with the new-onset of SLE during pregnancy and its impacts on the pregnancy outcomes.

In this study, we aimed to study the maternal and fetal outcomes of new-onset SLE and lupus nephritis during pregnancy in Chinese SLE women.

Patients and Methods

We retrospectively reviewed the medical records of 109 consecutive pregnancies in 83 SLE patients from a tertiary hospital between 2004 and 2014. All patients met at least four of the 1997 revised American College of Rheumatology criteria for the classification of SLE[21]. Those terminated electively were not included in this analysis. Patients with renal insufficiency during pregnancy were also excluded from our study. This study complied with the Declaration of Helsinki Principles and was approved by the Ethics Committee of Tongji Hospital, Huazhong University of Science and Technology. Written informed consent was obtained from each patient.

Medical records were reviewed retrospectively; demographic data, clinical and laboratory information were collected. Laboratory data, including hemoglobin, red and white blood cell and platelet counts, urinalysis, 24-h urine protein excretion, serum creatinine, blood urea nitrogen, albumin, glucose, and uric acid as well as immunologic parameters including complement 3 (C3), complement 4 (C4), immune globulin, Coomb’s test, antinuclear antibodies (ANA), anti-ds DNA antibodies (anti-dsDNA), anti-Smith antibody, anti-Ro/SSA antibodies, anti-La/SSB antibodies, anticardiolipin antibody (aCL), and anti-β2 glycoprotein 1 antibody.

Patients were divided into new-onset SLE group who were firstly diagnosed with SLE during pregnancy or puerperium and pre-existing SLE group who had a history of SLE. The pre-existing SLE group was further divided into lupus nephritis groups and non-renal involvement SLE group. Lupus nephritis was define as the presence of active urinary sediment and/or proteinuria >0.5 g/day with or without elevation in serum creatinine before 20 weeks gestation. Before ascribing proteinuria, preeclampsia and HELLP (hemolysis, elevated liver enzymes, and low platelets) syndrome had been excluded. SLE disease activity was evaluated according to the SLE Disease Activity Index 2000 (SLEDAI-2K)[22].

Maternal outcomes included SLE flares, disease activity, hypertension, preeclampsia, thrombocytopenia and anemia. Anemia was defined as hemoglobin <100 g/L during pregnancy.

Fetal outcomes for live birth included fetal loss, prematurity, 1-min Apgar scores and intrauterine growth retardation. Fetal loss was the loss of pregnancy due to spontaneous abortion or stillbirth. Gestational age of fetal loss or delivery was also recorded. Spontaneous abortion was defined as the spontaneous loss of a fetus before 20 weeks of gestation, stillbirth as the death of the fetus in utero after 20 weeks of gestation, and elective abortion as the voluntary termination of pregnancy. Preterm birth was a live birth between 23 and 37 weeks and intrauterine growth retardation (IUGR) was defined as birth weight less than 2500g.
Statistical analysis

Statistical analysis was performed with SPSS version 20. The categorical variables were analyzed by using chi-square test or Fisher’s exact probability test as appropriate. The continuous variables were analyzed by using Student’s t test as appropriate. A value of p<0.05 was regarded as statistically significant.

Results

Patient characteristics

A total of 83 patients had 109 pregnancies during our study. As shown in Table 1, the mean age of the patients when diagnosed with SLE was 21.38 ± 5.90 years (range, 9 to 40 years), and the mean age at the time of conception was 28.16 ± 4.96 years (range, 19 to 41 years). The mean SLE duration was 4.26±3.89 years (range, 0 to 21 years). The mean SLEDAI-2K scores at conception was 10.05±6.96. Among these patients, 63 patients were nulliparous and 20 patients

Table 1. Patients’ characteristics during pregnancy.

| Characteristic                               | Value or no. (%) of patients (n = 83) |
|---------------------------------------------|--------------------------------------|
| Age at disease onset (yr, mean±SD, range)   | 21.38±5.90 (9–40)                    |
| Age at conception (yr, mean±SD, range)      | 28.16±4.96 (19–41)                   |
| Disease duration (yr, mean±SD, range)       | 4.26±3.89 (0–21)                     |
| First pregnancy                             | 63 (75.9%)                           |
| Second pregnancy                            | 15 (18.1%)                           |
| Third or more pregnancy                     | 5 (6.0%)                             |
| Cesarean section                            | 50 (60.24%)                          |
| SLEDAI-2K at conception (score, mean±SD, range) | 10.05±6.96 (0–33)                   |
| New onset SLE                               | 19 (22.9%)                           |
| Neonatal lupus                              | 2 (3%)                               |
| Neonatal heart disease                      | 2 (3%)                               |
| APS                                         | 4 (4.8%)                             |

Laboratory features at onset of pregnancy

| Ab                                           | Value or no. (%) of patients (n = 83) |
|----------------------------------------------|--------------------------------------|
| ANA                                          | 83 (100%)                            |
| Anti-dsDNA                                    | 72 (86.7%)                           |
| Anti-Ro/SSA                                   | 55 (66.2%)                           |
| Anti-La/SSB                                   | 24 (28.9%)                           |
| Anti-Sm                                       | 27 (32.5%)                           |
| aCL                                          | 10 (12%)                             |
| Hypocomplementania                           | 56 (67.5%)                           |
| C3                                           | 25 (30.1%)                           |
| C4                                           | 40 (48.2%)                           |

Drugs taken at the onset of pregnancy

| Drugs taken at the onset of pregnancy        | Value or no. (%) of patients (n = 83) |
|----------------------------------------------|--------------------------------------|
| Prednisone                                   | 57 (68.7%)                           |
| Aspirin                                      | 10 (12%)                             |
| Azathioprine                                 | 5 (6%)                               |
| Cyclophosphamide                             | 0                                    |
| Methotrexate                                 | 0                                    |
| Chloroquine                                  | 30 (36.1%)                           |

SLEDAI, systemic lupus erythematosus disease activity index; Ab, antibodies; aCL, Anticardiolipin antibody.
were multiparous. Fifteen patients had two pregnancies, four patients had three pregnancies, and one patient had four pregnancies.

Autoantibodies during pregnancy were positive as follows: anti-ds DNA in 72 patients (86.7%), anti-Ro/SSA in 55 patients (66.2%), anti-La/SSB in 24 patients (28.9%), and anti-Sm in 27 patients (32.5%). Hypocomplementemia was observed in 56 patients (67.4%). Four patients were diagnosed as antiphospholipid syndrome (APS) during pregnancy and one mother’s baby died in utero during the 26th week.

Of the 83 women during pregnancy, 57 (68.7%) were treated with low-dose glucocorticoid, with an average prednisone dose of 5 mg/d (range 2.5–15 mg). A total of 30 patients (36.1%) were taking hydroxychloroquine (HCQ) (200 mg/d). Flares were treated with prednisone (0.5-1mg/kg/d). Aspirin (100mg/d) was prescribed for patients positive for aCL antibodies.

Pregnancy outcomes and factors associated with adverse pregnancy outcome

Fetal loss (including spontaneous abortion and stillbirth) occurred in 42 pregnancies (38.5%), and the live birth pregnancies (including premature births, live birth at full term and postmature births) occurred in 67 pregnancies (61.5%) (Table 2). There were two neonatal lupus and two fetal heart malformations (one tetralogy of Fallot, and one atrial septal defect). The neonatal with tetralogy of Fallot died at the second day after birth. APS, disease activity at conception, thrombocytopenia, hypocomplementemia, anemia, and hypertension were significantly associated with fetal loss at univariate analysis, while binary logistic regression analysis showed APS, disease activity at conception, thrombocytopenia, anemia, and hypertension were significant predictors of fetal loss.

Adverse pregnancy outcomes between new-onset SLE and pre-existing SLE patients

Of the 83 patients, 19 (22.9%) women were firstly diagnosed with SLE during pregnancy or puerperium, and 64 (77.1%) women were pre-existing SLE. Among the 19 new-onset SLE patients, 12 patients had SLE that first occurred during the second trimester (63.1%), mainly during the 18th week. Compared to pre-existing SLE pregnancies, patients with new-onset SLE during pregnancy had a significantly higher fetal loss (73.7% vs 15.6%, p<0.01) (Table 3).

Table 2. Comparison of clinical features between fetal loss pregnancies and live birth pregnancies.

| Clinical features               | Fetal loss pregnancies (n = 42 cases) | Live birth pregnancies (n = 67 cases) | Univariate analysis p | Logistic regression analysis p |
|--------------------------------|-------------------------------------|-------------------------------------|-----------------------|--------------------------------|
| APS                            | 4 (9.5%)                            | 0                                   | <0.001                | 0.012                          |
| Hypocomplementemia             | 35 (83.3%)                          | 22 (32.8%)                          | 0.001                 | -                              |
| SLEDAI-2K at conception (mean±SD, range) | 14.9±7.8                            | 8.0±5.5                             | <0.001                | 0.002                          |
| Anti-dsDNA                     | 37 (88.1%)                          | 60 (89.6%)                          | 1.0                   | -                              |
| Proteinuria                    | 34 (80.1%)                          | 41 (61.2)                           | 0.13                  | -                              |
| Thrombocytopenia               | 21 (50%)                            | 12 (17.9%)                          | 0.01                  | 0.02                           |
| Hypertension                   | 21 (50%)                            | 16 (23.9%)                          | 0.04                  | 0.001                          |
| Anemia                         | 34 (80.1%)                          | 23 (34.3%)                          | 0.04                  | 0.007                          |
| Lupus Nephritis                | 16 (38.1%)                          | 21 (31.3%)                          | 0.59                  | -                              |

Pregnancies loss include spontaneous abortion (<12 weeks), interuterine fetal death (≥12 weeks) and perinatal deaths. Live birth pregnancies include premature births (≥22 weeks, <37 weeks) and full-term births (≥37 weeks, <42 weeks). SLEDAI, systemic lupus erythematosus disease activity index.

doi:10.1371/journal.pone.0159364.t002
Disease activity, such as high SLEDAI scores and hypocomplementemia were commonly founded among new-onset SLE patients during pregnancy. The levels of hemoglobin and neonate Apgar score (1 min after birth) were significantly lower in the new-onset SLE pregnancies and the rate of lupus nephritis was significant higher in new-onset SLE group. The remaining manifestations were not significant differences between the two groups. All the patients in pre-existing SLE group were still alive after delivery. Unfortunately, one patient of the new-onset SLE group died during pregnancy.

Pregnancy outcomes in non-renal involvement SLE group and lupus nephritis group

The 64 pre-existing SLE patients were divided into two groups by kidney impairment. We found that lupus nephritis pregnancies have more maternal adverse outcomes, including proteinuria, hypertension, disease activity and SLE flares, compared to SLE group. However, the fetal outcome between the two groups was not significantly different (Table 4).

**Table 3. Comparison of pregnancy outcomes between new onset SLE and pre-existing SLE patients.**

|                      | New-onset SLE (n = 19 cases) | Pre-existing SLE (n = 64 cases) | p   |
|----------------------|-----------------------------|--------------------------------|-----|
| **Maternal outcome** |                             |                                |     |
| SLEDAI-2K at conception | 15.4±7.4                    | 8.4±5.9                        | <0.001 |
| Hypocomplementemia   | 12 (63.2%)                  | 18 (28%)                       | 0.01 |
| Thrombocytopenia     | 7 (36.9%)                   | 14 (22.6%)                     | 0.21 |
| Anemia               | 15 (78.9%)                  | 24 (37.5%)                     | 0.01 |
| Hypertension         | 8 (42.1%)                   | 16 (18.4%)                     | 0.16 |
| Proteinuria          | 16 (88.9%)                  | 35 (59.3%)                     | 0.04 |
| Lupus nephrities     | 12 (66.7%)                  | 21 (40.4%)                     | 0.05 |
| Maternal death       | 1 (5.3%)                    | 0                              | 0.07 |
| **Fetal outcome**    |                             |                                |     |
| Fetal loss           | 14 (73.7%)                  | 10 (15.6%)                     | <0.01 |
| Premature (22–37 W)  | 3 (20%)                     | 18 (28.6%)                     | 0.5  |
| Apgar score 1-min    | 3.6±4.17                    | 7.4±2.8                        | 0.01 |
| IUGR                 | 11 (57.9%)                  | 25 (39.1%)                     | 0.15 |
| Neonatal lupus       | 0                           | 2 (3.1%)                       | 0.44 |
| Neonatal heart disease | 0                         | 2 (3.1%)                       | 0.44 |

IUGR, intrauterine growth retardation.

Pregnancy outcomes in non-renal involvement SLE group and lupus nephritis group

Discussion

Recent studies suggest progress in understanding the association between pregnancy and SLE and better treatment choices. Pregnancy outcomes have become more favorable during recent years. However, poor mother outcomes and fetal loss remains higher than in the general population. In addition, new-onset of SLE during pregnancy is still very common but reported scarcely. Published reports on pregnancy outcomes in Chinese women with SLE and lupus nephritis have some limitations. For example, Tian’s research group demonstrated the related factors of fetal loss but not reported the maternal outcomes in Chinese women with SLE[23]. Liu’s research group demonstrated the adverse outcome between active and inactive SLE pregnancies, however, they didn’t focus on the difference of outcome between pre-existing SLE pregnancies and new-onset SLE during pregnancy, LN pregnancies and non-renal involvement SLE pregnancies[24]. In our study, we retrospectively reviewed 83 SLE patients of 109
pregnancies during the last decade in our university hospital in China. After excluding elective abortions, our live birth rate was 61.5%, which is lower than the 80.5%-91.9% reported in previous studies\([4–6]\), and our fetal loss of 38.5% is high compared to previous retrospective reports of 8%-40\([24–26]\). The low live birth rate can be explained by the reasons below: On one hand, our hospital is a major tertiary comprehensive center having a lot of patients with more severe and complicated disease. Our hospital may represent more than 800 tertiary hospitals in China. On the other hand, a high proportion of new-onset SLE patients during pregnancies who have lower birth rate. When the new-onset SLE pregnancies group is excluded, the live birth rate is 84.4%.

Hydroxychloroquine has been used extensively for SLE where it has a good reputation for controlling the dermatological complications in SLE in recent years. Our prevalence of hydroxychloroquine use was 36%, which is lower than 55% in the US\([27]\). However, it is similar to that hydroxychloroquine prescribed from 18% to 32.2% in Spain\([28]\). There are several reasons below: Firstly, our patients ranged from January 2004 to January 2014. In the previous few years, hydroxychloroquine was not widely used in our country. Secondly, hydroxychloroquine was prescribed more frequently by rheumatologists than by primary care physicians or nephrologists in China. Thirdly, the long disease course and the tough economic condition of SLE patients may cause poor compliance. Our study suggests the importance for both rheumatologists and nonrheumatologists such as primary care physicians and nephrologists to consider the use of hydroxychloroquine more frequently in their SLE patients.

There was a small proportion of APS patients in our study. Previous studies have demonstrated APS was a major risk for fetal loss and mother health\([29,30]\). Indeed, in our study one mother with APS lost her baby and then died of bleeding. Studies of the pathogenesis of APS indicate that lupus anticoagulant, anticardiolipin antibody and antiphospholipid antibody play a direct pathogenic role resulting in placental insufficiency\([29,31]\).

Table 4. Comparison of pregnancy outcomes between SLE group and lupus nephritis group.

| Pregnancy outcome | Non-renal involvement SLE group (n = 35 cases) | Lupus nephritis (n = 29 cases) | p |
|-------------------|------------------------------------------------|------------------------------|---|
| **Maternal outcome** |                                               |                              |   |
| SLEDAI-2K         | 6.5±5.4                                       | 10.5±5.9                     | 0.009 |
| SLE flares        | 12 (34.3%)                                    | 18 (62.1%)                   | 0.001 |
| UA                | 316±118                                       | 360±114                      | 0.13 |
| Proteinuria       | 13 (37.1%)                                    | 22 (75.9%)                   | 0.005 |
| ALB               | 33.3±4.3                                      | 31.2±6.3                     | 0.14 |
| Anemia            | 11 (31.4%)                                    | 13 (44.8%)                   | 0.27 |
| Thrombocytopenia  | 4 (11.4%)                                      | 10 (34.5%)                   | 0.30 |
| Hypertension      | 5 (14.3%)                                      | 11 (37.9%)                   | 0.025 |
| Hypocomplementania| 8 (22.9%)                                      | 10 (34.5%)                   | 0.52 |
| Serum creatinine  | 49.7±20.3                                     | 58.6±27.5                    | 0.43 |
| **Fetal outcome** |                                               |                              |   |
| Fetal loss        | 3 (8.6%)                                       | 6 (20.7%)                    | 0.17 |
| Premature         | 9 (25.7%)                                      | 9 (31.0%)                    | 0.15 |
| IUGR              | 10 (28.6%)                                     | 9 (31.0%)                    | 0.78 |
| Apgar score (mean±SD) | 7.6±2.7                             | 7.4±2.4                      | 0.72 |
| Neonatal lupus    | 2(5.7%)                                        | 0                            | 0.18 |
| Neonatal heart disease | 2(5.7%)                             | 0                            | 0.18 |

IUGR, intrauterine growth retardation; ALB, albumin; UA, uric acid.

doi:10.1371/journal.pone.0159364.t004
In this study, new-onset SLE during pregnancy or puerperium occurred in 19 (22.9%) of our patients, suggesting that first diagnosis of SLE was not a rare event during pregnancy. This group of patients often has poor prognosis. The recognition of new-onset SLE during pregnancy can sometimes be difficult because the symptoms and signs may mimic those of normal pregnancy. Edema, fatigue, hair loss, erythema, mild anemia, decreased albumin concentrations, and headaches frequently accompany normal pregnancy[32,33]. When the condition persists or gets worse, such as severe anemia, thrombocytopenia, and proteinuria, the new-onset SLE pregnancies then referred to a tertiary hospital. In addition, we also found that new-onset lupus primarily occurred during the second trimester. It is reported that estrogens are a predisposing factor for SLE occurrence[34,35]. However, reports about new-onset SLE during pregnancy and its impacts on maternal and fetal health are lacking. Hormonal swings of pregnancy in the second trimester accompanying with the alteration of immune system, may be the risk factor for new onset SLE during pregnancy[36]. Our study demonstrated that new-onset SLE patients have more severe disease with frequent renal and platelet involvement, which is in line with one previous report[20].

The impact of lupus nephritis on maternal and fetal outcomes is controversy. Several previous studies suggested that lupus nephritis may contribute to adverse pregnancy outcomes [13,17,37,38]. In particular, active lupus nephritis leads to severe pregnancy outcomes[12,39–41]. By contrast, some reports showed that the lupus nephritis has no impact on maternal or fetal outcomes[14–16]. We provided the data of LN on pregnancy outcome in a large group of SLE patients in a tertiary center. Based on our results, lupus nephritis was another risk factor for adverse maternal outcomes, such as SLE flares, hypertension, and anemia, but it was not significant association with adverse fetal outcomes.

Neonatal lupus and two neonatal malformations are still challenging to physicians. There are two neonatal lupus and two fetal heart malformations (one tetralogy of Fallot, and one atrial septal defect). The neonatal with tetralogy of Fallot died at the second day after birth. Neonatal lupus and neonatal heart disease do not appear to be significantly associated with the new-onset lupus during pregnancy or LN pregnancies, which may be associated with the anti-Ro/SSA and anti-La/SSB[42,43] and needs further investigation.

There are several limitations to our study. Firstly, as a retrospective investigation, some patients were referred to our hospital in the midst of their pregnancy and those patients’ information at the starting of pregnancy were lacking. Secondly, our single-center study may have bias. Our patients with increased lupus activity during pregnancy may be due to the major tertiary hospital receiving patients from other community hospitals. So, it should be noted that our patients may not represent the general population well.

In conclusion, pregnancies can be successful in most women with pre-existing SLE. However, the new-onset of lupus during pregnancy generally have poor prognosis, with high maternal and fetal morbidity and mortality. Furthermore, a history of lupus nephritis could predict adverse maternal outcomes. To obtain favorable pregnancy outcomes, lupus quiescence, no significant proteinuria and satisfactory blood pressure control should be achieved before conception and regularly monitored by experienced obstetricians, nephrologist and rheumatologists is needed.

Supporting Information

S1 File. The data of new onset SLE group and pre-existing SLE group.
(SAV)

S2 File. The data of SLE group and lupus nephritis group.
(SAV)
Author Contributions
Conceived and designed the experiments: MK SWG SMG GX. Performed the experiments: MK QL. Analyzed the data: MK. Contributed reagents/materials/analysis tools: MK WFS MH RZ GX. Wrote the paper: MK SWG.

References
1. Smyth A, Garovic VD (2009) Systemic lupus erythematosus and pregnancy. Minerva Urol Nefrol 61: 457–474. PMID: 19816395
2. Derksen RH, Bruinse HW, de Groot PG, Kater L (1994) Pregnancy in systemic lupus erythematosus: a prospective study. Lupus 3: 149–155. PMID: 7951299
3. Wong CH, Chen TL, Lee CS, Lin CJ, Chen CP (2006) Outcome of pregnancy in patients with systemic lupus erythematosus. Taiwan J Obstet Gynecol 45: 120–123. PMID: 17197351
4. Yan Yuen S, Krizova A, Ouimet JM, Pope JE (2008) Pregnancy outcome in systemic lupus erythematosus (SLE) is improving: Results from a case control study and literature review. Open Rheumatol J 2: 89–98. doi: 10.2174/1874312900802010089 PMID: 19156224
5. Teh CL, Wong JS, Ngeh NK, Loh WL (2009) Systemic lupus erythematosus pregnancies: a case series from a tertiary, East Malaysian hospital. Lupus 18: 278–282. doi: 10.1177/0961203308096661 PMID: 19213870
6. Ambrosio P, Lermann R, Cordeiro A, Borges A, Nogueira I, Serrano F (2010) Lupus and pregnancy—15 years of experience in a tertiary center. Clin Rev Allergy Immunol 38: 77–81. PMID: 19557319
7. Ko HS, Ahn HY, Jang DG, Choi SK, Park YG, Park IY, et al. (2011) Pregnancy outcomes and appropriate timing of pregnancy in 183 pregnancies in Korean patients with SLE. Int J Med Sci 8: 577–583. PMID: 22022210
8. Bear R (1976) Pregnancy and lupus nephritis. A detailed report of six cases with a review of the literature. Obstet Gynecol 47: 715–718. PMID: 934563
9. Le Thi Huong D, Wechsler B, Piette JC, Bletry O, Godeau P (1994) Pregnancy and its outcome in systemic lupus erythematosus. Qjm 87: 721–729. PMID: 7859048
10. Foccharoen C, Nanagara R, Salang L, Suwanaraj J, Mahakkanukrauh A (2009) Pregnancy and disease outcome in patients with systemic lupus erythematosus (SLE): a study at Srinagarind Hospital. J Med Assoc Thai 92: 167–174. PMID: 19253790
11. Andrade R, Sanchez ML, Alarcon GS, Fessler BJ, Fernandez M, Bertoli AM, et al. (2008) Adverse pregnancy outcomes in women with systemic lupus erythematosus from a multiethnic US cohort: LUMINA (LVI) [corrected]. Clin Exp Rheumatol 26: 268–274. PMID: 18565248
12. Wagner SJ, Craici I, Reed D, Norby S, Bailey K, Wiste HJ, et al. (2009) Maternal and foetal outcomes in pregnant patients with active lupus nephritis. Lupus 18: 342–347. doi: 10.1177/0961203308096895 PMID: 19276302
13. Smyth A, Oliveira GH, Lahr BD, Bailey KR, Norby SM, Garovic VD (2010) A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 5: 2060–2068. doi: 10.2215/CJN.00240110 PMID: 20688867
14. Imbasciati E, Tincani A, Gregorini G, Doria A, Moroni G, Cabiddu G, et al. (2009) Pregnancy in women with pre-existing lupus nephritis: predictors of fetal and maternal outcome. Nephrol Dial Transplant 24: 519–525. doi: 10.1093/ndt/gfn348 PMID: 18565977
15. Tandon A, Ibanez D, Gladman DD, Urowitz MB (2004) The effect of pregnancy on lupus nephritis. Arthritis Rheum 50: 3941–3946. PMID: 15593212
16. Oviasu E, Hicks J, Cameron JS (1991) The outcome of pregnancy in women with lupus nephritis. Lupus 1: 19–25. PMID: 1845358
17. Huong DL, Wechsler B, Vauthier-Brouzes D, Beaufils H, Lefebvre G, Piette JC (2001) Pregnancy in past or present lupus nephritis: a study of 32 pregnancies from a single centre. Ann Rheum Dis 60: 599–604. PMID: 11350849
18. Yang MJ, Cheng MH, Lin HY (2006) Onset of systemic lupus erythematosus during pregnancy. J Chin Med Assoc 69: 130–133. PMID: 16599019
19. Matsuo S, Uchida E, Shimajiri S, Nishihara G (2007) A case of a pregnant woman developing systemic lupus erythematosus during pregnancy. Clin Nephrol 67: 331–332. PMID: 17542344
20. Zhao C, Zhao J, Huang Y, Wang Z, Wang H, Zhang H, et al. (2013) New-onset systemic lupus erythematosus during pregnancy. Clin Rheumatol 32: 815–822. doi: 10.1007/s10067-013-2180-z PMID: 23358882

21. Hochberg MC (1997) Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 40: 1725.

22. Gladman DD, Ibanez D, Urowitz MB (2002) Systemic lupus erythematosus disease activity index 2000. J Rheumatol 29: 288–291. PMID: 11838846

23. Tian X, Li M, Ye Z, Zhang X, Liu S, Wu L, et al. (2014) Related factors of fetal loss in Chinese women with systemic lupus erythematosus: data from Chinese SLE Treatment and Research Group registry IV. Int J Rheum Dis.

24. Liu J, Zhao Y, Song Y, Zhang W, Bian X, Yang J, et al. (2012) Pregnancy in women with systemic lupus erythematosus: a retrospective study of 111 pregnancies in Chinese women. J Matern Fetal Neonatal Med 25: 261–266. doi: 10.3109/14767058.2011.572310 PMID: 21504337

25. Cortes-Hernandez J, Ordi-Ros J, Paredes F, Casellas M, Castillo F, Vilardell-Tarres M (2002) Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 41: 643–650.

26. Mok MY, Leung PY, Lao TH, Lo Y, Chan TM, Wong WS, et al. (2004) Clinical predictors of fetal and maternal outcome in Chinese patients with systemic lupus erythematosus. Ann Rheum Dis 63: 1705–1706. PMID: 15547105

27. Schmajuk G, Yazdany J, Trupin L, Yelin E (2010) Hydroxychloroquine treatment in a community-based cohort of patients with systemic lupus erythematosus. Arthritis Care Res (Hoboken) 62: 386–392.

28. Molina MJ, Mayor AM, Franco AE, Morell CA, Lopez MA, Vila LM (2008) Utilization of health services and prescription patterns among lupus patients followed by primary care physicians and rheumatologists in Puerto Rico. Ethn Dis 18: S2-205–210.

29. Lockshin MD, Kim M, Laskin CA, Guerra M, Branch DW, Merrill J, et al. (2012) Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not antiphospholipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 64: 2311–2318. doi: 10.1002/art.34402 PMID: 22275304

30. Sciascia S, Murr V, Sanna G, Roccatallo D, Khamashta MA, Bertolaccini ML (2012) Clinical accuracy for diagnosis of antiphospholipid syndrome in systemic lupus erythematosus: evaluation of 23 possible combinations of antiphospholipid antibody specificities. J Thromb Haemost 10: 2512–2518. doi: 10.1111/j.1538-7836.2011.04546.x

31. Di Simone N, Raschi E, Testoni C, Castellani R, D’Asta M, Shi T, et al. (2005) Pathogenic role of anti-beta 2-glycoprotein I antibodies in antiphospholipid associated fetal loss: characterisation of beta 2-glycoprotein I binding to trophoblast cells and functional effects of anti-beta 2-glycoprotein I antibodies in vitro. Ann Rheum Dis 64: 462–467. PMID: 15256379

32. Chang J, Streitman D (2012) Physiologic adaptations to pregnancy. Neurol Clin 30: 781–789. doi: 10.1016/j.ncl.2012.05.001 PMID: 22840789

33. Costantini MM (2014) Physiologic and pharmacokinetic changes in pregnancy. Front Pharmacol 5: 65. doi: 10.3389/fphar.2014.00065 PMID: 24772083

34. Costenbader KH, Feskanich D, Stampfer MJ, Karlson EW (2007) Reproductive and menopausal factors and risk of systemic lupus erythematosus in women. Arthritis Rheum 56: 1251–1262. PMID: 17393454

35. Bernier MO, Mikaeloff Y, Hudson M, Suissa S (2009) Combined oral contraceptive use and the risk of systemic lupus erythematosus. Arthritis Rheum 61: 476–481. doi: 10.1002/art.24398 PMID: 19333988

36. Jara LJ, Medina G, Cruz-Dominguez P, Navarro C, Vera-Lastra O, Saavedra MA (2014) Risk factors of systemic lupus erythematosus flares during pregnancy. Immunol Res 60: 813–819. doi: 10.1007/s12026-014-8577-1 PMID: 25391611

37. Zhang L, Abe K, Hashimoto H, Takasaki Y (2007) [Pregnancy and fetal outcomes in patients with lupus nephritis]. Nihon Rinsho Meneki Gakkai Kaishi 30: 185–192. PMID: 17603259

38. Carmona F, Font J, Moya I, Lazaro I, Cervera R, Pac V, et al. (2005) Class III-IV proliferative lupus nephritis and pregnancy: a study of 42 cases. Am J Reprod Immunol 53: 182–188. PMID: 15760379

39. Saavedra MA, Cruz-Reyes C, Vera-Lastra O, Romero GT, Cruz-Cruz P, Arias-Flores R, et al. (2012) Impact of previous lupus nephritis on maternal and fetal outcomes during pregnancy. Clin Rheumatol 31: 813–819. doi: 10.1007/s10067-012-1941-4 PMID: 2227163

40. Moroni G, Quaglini S, Banfi G, Caloni M, Finazzi S, Ambrosio G, et al. (2002) Pregnancy in lupus nephritis. Am J Kidney Dis 40: 713–720. PMID: 12324905

41. Clowse ME, Magder LS, Witter F, Petri M (2005) The impact of increased lupus activity on obstetric outcomes. Arthritis Rheum 52: 514–521. PMID: 15692988
42. Luo Y, Zhang L, Fei Y, Li Y, Hao D, Liu Y, et al. (2015) Pregnancy outcome of 126 anti-SSA/Ro-positive patients during the past 24 years—a retrospective cohort study. Clin Rheumatol 34: 1721–1728. doi: 10.1007/s10067-015-3050-7 PMID: 26384980

43. Feki S, Turki A, Frikha F, Hachicha H, Walha L, Gargouri A, et al. (2015) [Neonatal lupus and materno-fetal transmission of anti-SSA/Ro and anti-SSB/La antibodies]. Arch Pediatr 22: 154–159. doi: 10.1016/j.arcped.2014.10.020 PMID: 25440767